Drugs / ZIRITAXESTAT
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03787186 | Nov 2018 → Jan 2019 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03515382 | Mar → Jun 2018 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03143712 | Apr → Jun 2017 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02179502 | Jun → Nov 2014 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03976648 | Jul 2019 → Apr 2021 | systemic sclerosis | Lakefront Biotherapeutics NV | Terminated | No outcome recorded |
| Phase 2 | NCT03798366 | Jan 2019 → May 2020 | systemic sclerosis | Lakefront Biotherapeutics NV | Completed | Mixed |
| Phase 2 | NCT02738801 | Mar 2016 → May 2017 | idiopathic pulmonary fibrosis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT03711162 | Nov 2018 → Mar 2021 | idiopathic pulmonary fibrosis | Lakefront Biotherapeutics NV | Terminated | Missed primary |
| Phase 3 | NCT03733444 | Nov 2018 → Mar 2021 | idiopathic pulmonary fibrosis | Lakefront Biotherapeutics NV | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2021-02-10 | Gilead Sciences | Results Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF gilead.com ↗
The decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies. |
| 2018-05-20 | Lakefront Biotherapeutics NV | Results GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS lakefrontbio.com ↗
Over the 12-week period, patients receiving GLPG1690 showed an FVC increase of 8 mL, while patients on placebo showed an FVC reduction of 87 mL (mean from baseline). |
| 2017-08-09 | Lakefront Biotherapeutics NV | Results GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial lakefrontbio.com ↗
Galapagos NV (Euronext & NASDAQ: GLPG) announces positive topline results with its autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF) in the FLORA Phase 2a trial. |
| 2016-09-06 | Lakefront Biotherapeutics NV | Regulatory Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis lakefrontbio.com ↗
Mechelen, Belgium; 6 September 2016: Galapagos (Euronext & NASDAQ: GLPG) announces today that the European Commission (EC) has granted GLPG1690 ‘orphan drug designation’ for the treatment of patients with idiopathic pulmonary fibrosis (IPF). |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-02-10 | Gilead Sciences | Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF gilead.com ↗ |
| 2018-05-20 | Lakefront Biotherapeutics NV | GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS lakefrontbio.com ↗ |
| 2017-10-26 | Lakefront Biotherapeutics NV | Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline lakefrontbio.com ↗ |
| 2017-08-09 | Lakefront Biotherapeutics NV | GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial lakefrontbio.com ↗ |
| 2016-09-06 | Lakefront Biotherapeutics NV | Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis lakefrontbio.com ↗ |
| 2016-04-06 | Lakefront Biotherapeutics NV | Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients lakefrontbio.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZIRITAXESTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3828074 ↗ |
| Known as | G-451990 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3828074 ↗ |
| Known as | GLPG1690 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03787186 ↗ |
| Known as | ZIRITAXESTAT (GLPG1690) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3828074 ↗ |
| Known as | ZIRITAXESTATN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3828074 ↗ |
| Action | Inhibit | “GLPG1690 is a novel autotaxin inhibitor in development for the treatment of idiopathic pulmonary fibrosis (IPF).” PMID 31012984 ↗ Apr 20191“Autotaxin inhibitor” CHEMBL3828074 ↗ |
| Modality | Small molecule | — CHEMBL3828074 ↗ |
| Route | Oral | “single (20, 60, 150, 300, 600, 1000, 1500 mg) and multiple (14 days: 150 mg twice daily; 600 and 1000 mg once daily) ascending oral doses of GLPG1690” PMID 31012984 ↗ Apr 2019 |
| Target | ENPP2 | “Autotaxin inhibitor” CHEMBL3828074 ↗ |